Cannabis Educational Modules for Allergy Professionals

Price: FREE to members and non-members

This set of modules is intended to provide tools and an information platform to educate allergists about cannabis use in patients, the rising concern of cannabis allergy, and ways to discuss cannabis with their patients in an effective manner. Even though allergy and asthma are not an indication for a medical cannabis card in any state, allergic/asthmatic individuals use cannabis for co-morbid conditions and recreationally.

It is important that allergists understand the nuances of cannabis use so they can guide their patients to use cannabis safely and effectively by maximizing benefits and minimizing harms.

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This course was developed with support from the Allergists’ Foundation Community Grant Program.

Target Audience

Practicing allergists, staff, and other allergy healthcare providers.

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Examples of such organizations include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships have been mitigated.

Anil Nanda, MD, FACAAI, has nothing to disclose.
Joanna Zeiger, MS, PhD, has nothing to disclose.
Hannalore Brucker, MD, FACP, has nothing to disclose.


Course summary
Available credit: 
  • 3.75 AMA PRA Category 1 Credit™
  • 3.75 Attendance
Course opens: 
Course expires: 

Anil Nanda, MD, FACAAI is in solo, community based private practice in Allergy and Immunology in the Dallas, Texas, area.  He is also Adjunct Professor of Medicine at University of Texas Southwestern Medical Center.  He is heavily involved in local, state, and national Allergy and Immunology organizations, including the ACAAl. He is currently President of the Texas Allergy, Asthma, and Immunology Society.

Joanna Zeiger, MS, PhD has spent over 15 years as a cannabis epidemiologist. She is the Founder & CEO and primary epidemiologist and biostatistician for Canna Research Foundation (CRF), a nonprofit organization. The aim of CRF is to understand the role of cannabis patterns of use and benefits/adverse effects in various populations to better understand the efficacy and safety of medical cannabis in order to disseminate information to clinicians, patients, and industry stakeholders.

Hannalore Brucker, MD, FACP is an internal medicine specialist in Minneapolis, MN and has 55 years experience. They graduated from Eberhard Karls U Tubingen in 1968 and completed a residency at Hennepin County Medical Center.

Available Credit

  • 3.75 AMA PRA Category 1 Credit™
  • 3.75 Attendance
Please login or create an account to take this course.